Apyx Medical Corp
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
APYX$2.94+0.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations for
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
| Three Months EndedMarch 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Sales | $10,244 | $12,142 | |
| Cost of sales | 4,295 | 4,569 | |
| Gross profit | 5,949 | 7,573 | |
| Other costs and expenses: | |||
| Research and development | 1,397 | 1,271 | |
| Professional services | 1,574 | 1,740 | |
| Salaries and related costs | 4,696 | 4,918 | |
| Selling, general and administrative | 4,897 | 5,255 | |
| Total other costs and expenses | 12,564 | 13,184 | |
| Loss from operations | (6,615) | (5,611) | |
| Interest income | 495 | 51 | |
| Interest expense | (1,396) | (234) | |
| Other loss, net | (21) | (5) | |
| Total other loss, net | (922) | (188) | |
| Loss before income taxes | (7,537) | (5,799) | |
| Income tax expense (benefit) | 53 | (2,267) | |
| Net loss | (7,590) | (3,532) | |
| Net loss attributable to non-controlling interest | (14) | (49) | |
| Net loss attributable to stockholders | $(7,576) | $(3,483) | |
| Loss per share: | |||
| Basic and diluted | $(0.22) | $(0.10) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.